Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Go back to Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
(NASDAQ: ADTX) Delayed: 0.02 +0.01 (100.00%)
Previous Close $0.01    52 Week High
Open $0.02    52 Week Low
Day High $0.02    P/E N/A 
Day Low $0.02    EPS
Volume 2,147,483,647